

Reference:	FOI.18834.25
Subject:	Chronic Obstructive Pulmonary Disease (COPD)
Date of Request:	14 November 2025

Requested:

1. Within your Trust, how many patients in total were admitted as inpatients between July – October 2025 with a primary cause of admission being a chronic obstructive pulmonary disease (COPD) exacerbation (ICD-10: J44.1)?
2. Of the patients admitted with a primary COPD exacerbation (ICD-10: J44.1) identified in Q1, how many were already prescribed a closed triple therapy* at the point of admission?

*Closed triple therapy = Trelegy, Trixeo, or Trimbow (any formulation)

*“Already prescribed” means the therapy was documented as active on admission, either from hospital records or patient-reported history.

3. How many patients in total were prescribed Trixeo for COPD (ICD-10: J44.1) between July – October 2025?
 - a. How many of these were new to Trixeo*?

*New to Trixeo = Patient not prescribed Trixeo in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trixeo—whether prescribed in hospital or community settings—at the point of admission.

4. How many patients in total were prescribed Trimbow MDI (for COPD [ICD-10: J44.1]) between July – October 2025?
 - a. How many of these were new to Trimbow MDI*?
 - b. Of the new Trimbow MDI patients*, what was the split between:
 - Trimbow MDI 87/5/9
 - Trimbow MDI 172/5/9

*New to Trimbow MDI = Patient not prescribed Trimbow MDI in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trimbow MDI—whether prescribed in hospital or community settings—at the point of admission.

5. How many patients in total were prescribed Trelegy for COPD (ICD-10: J44.1) between July – October 2025?
 - a. How many of these were new to Trelegy*?

*New to Trelegy = Patient not prescribed Trelegy in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trelegy—whether prescribed in hospital or community settings—at the point of admission.

6. How many patients in total were prescribed Trimbow DPI (for COPD [ICD-10: J44.1]) between July – October 2025?
 - a. How many of these were new to Trimbow DPI*?

*New to Trimbow DPI = Patient not prescribed Trimbow DPI in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trimbow DPI—whether prescribed in hospital or community settings—at the point of admission.

Response:

1. Hywel Dda University Health Board (UHB) confirms that fifty-five (55) patients were admitted to a UHB hospital with a primary diagnosis of COPD exacerbation, as recorded on the Welsh Patient Administration System (WPAS) with the ICD-10 code: J44 , during the period 1 July to 31 October 2025.
2. The UHB does not hold the requested information as historical medication data is not stored at patient level. Therefore, the UHB is unable to determine whether a patient was on this medication at the point of admission. However, the UHB can confirm that of those admitted, thirty-seven (37) were issued a closed triple therapy, during the period 1 July to 31 October 2025.
3. The UHB confirms that a total of seventeen (17) inpatients were prescribed the medication Trixeo, during the period 1 July to 31 October 2025.
Please note:- patients may have brought their own inhalers into hospital, therefore the UHB would not have issued medication to these patients.
 - a. The UHB does not hold this information as historical medication data is not stored at patient level. Therefore, the UHB is unable to determine whether a patient was new to this medication at the point of admission
4. The UHB confirms that a total of fifteen (15) inpatients were prescribed the medication Trimbow MDI, during the period 1 July to 31 October 2025. Please see note above.
 - a. & b. The UHB does not hold this information as historical medication data is not stored at patient level. Therefore, the UHB is unable to determine whether a patient was new to this medication at the point of admission. However, the UHB can confirm that of the patients identified in response to question 4, nine (9) were prescribed Trimbow MDI 87/5/9 and six (6) were prescribed Trimbow MDI 172/5/9.
5. & 6. The UHB is unable to provide you with the number of patients, due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. Therefore, the UHB is withholding these details under Section 40(2) of the Freedom of Information Act 2000 (FoIA).

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.